All relevant data are within the manuscript and its Supporting Information files.

Introduction {#sec001}
============

For a new drug to enter the market, a local health agency must assess the efficacy and safety based on studies submitted by pharmaceutical companies. The North American agency, the US Food and Drug Administration (FDA), is the in the great majority the first agency in the world to approve new drugs \[[@pone.0236345.ref001]\].

Cancer is the leading cause of death in high-income countries \[[@pone.0236345.ref002]\]. Lung cancer incidence is increasing worldwide, with over two million new cases in 2018 \[[@pone.0236345.ref003]\]. The treatment arsenal for lung cancer is extensive, with an improved understanding of the genetic drivers (e.g. EGFR, ALK, BRAF) leading to a rapid growth in novel medications. Targeted and immune therapies are first-line treatments and widely recommended in current guidelines \[[@pone.0236345.ref004]--[@pone.0236345.ref006]\].

Considering recent FDA approvals, protein kinase inhibitors for advanced lung cancer accounted for 53% of new therapies for the four most common neoplasms and 78% were granted a special designation for faster approval \[[@pone.0236345.ref007]\]. Other studies have shown that these innovative trials of new FDA-approved anti-cancer drugs focus heavily on surrogate markers of clinical benefit, and trials that measure overall survival demonstrate only modest improvements \[[@pone.0236345.ref008]\].

In 1992, during the HIV crisis, the FDA created the \"Expedited Programs for Serious Conditions\". The aim was to provide faster access to medications that addressed 'unmet medical need' though an accelerated approval pathway and priority review designation in which studies using surrogate endpoints were considered. Subsequently other designations have been created to increase the flexibility of the approvals process. Under the "Breakthrough" designation, implemented in 2012, approvals can be based on preliminary clinical evidence--for example phase 2 or single-arm studies--that "indicates the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint(s)" \[[@pone.0236345.ref009]\]. While double blind randomized controlled trials (RCT) are the gold standard for intervention studies \[[@pone.0236345.ref010]\], these expedited programs result in more drug approvals based on single arm trials, with small sample sizes and surrogate endpoints \[[@pone.0236345.ref011]--[@pone.0236345.ref012]\].

Accelerated pathway differently from regular pathway allows anticancer drugs to be approved based on a surrogate endpoint, however it is unclear whether there is a difference in 1) proportion of surrogate endpoints, 2) sample size, 3) study design and, 4) effect size. Our two main comparisons were trials that received accelerated approval vs. regular approval and trials that received breakthrough designation vs. those that did not.

Methods {#sec002}
=======

This study used publicly available data and did not involve individual patient information. Ethics approval was not required. This report follows the STROBE statement for observational data reporting.

Data collection {#sec003}
---------------

Two authors (TR and LB) independently reviewed the FDA's online bulletin (\@DrugsFDA) that includes all approvals for lung cancer. The FDA database contains approval data on new drugs and indications since 2006. We retrieved information on approvals and trials supporting these approvals from January 1, 2006 to December 31, 2018. We excluded the following approval types: agnostic therapies, treatments for neuroendocrine tumors, changes to the dosing regimen of previously approved drugs or further specification of mutations (e.g. L858R), and finally we excluded conversion from accelerated to regular in order to due to duplicate the approval for the specific condition. First approvals of new lung cancer (NSCLC and SCLC) drugs as well as novel indications were included. One approval was not included in the FDA material but identified after cross-referencing. The following data were collected about studies forming the basis of approvals: sample size, study type (open-label RCT, double-blind RCT or single-arm), the intervention and control, whether overall survival was measured as an endpoint and the primary endpoint used to justify the FDA approval (overall survival---OS, progressive-free survival---PFS, overall response rate---OvRR or objective response rate---ORR), and the measure of effect. Generally, according to RECIST, OvRR is related to partial or complete response. ORR is defined as the sum of complete and partial responses \[[@pone.0236345.ref013]\]. However, the definition varies among studies and the authors often did not specify which definition they used.

We recorded the approval pathway (regular vs accelerated) and special designations (breakthrough or priority review). These data were subsequently confirmed on the accelerated approval (<https://www.fda.gov/drugs/nda-and-bla-approvals/accelerated-approvals>) and breakthrough therapy designation (BTD) databases (<https://www.fda.gov/drugs/nda-and-bla-approvals/breakthrough-therapy-approvals>). We checked if the drug was a new molecular entity (NME) approved for the first time in the USA by searching the generic names on the \@Drugs FDA database.

Magnitude of effect {#sec004}
-------------------

We assessed the magnitude of effect for the specified primary outcome. According to the GRADE classification \[[@pone.0236345.ref014]\] a relative risk (RR) greater than or equal to two was considered "large" and those less than two were considered "not large"; and a hazard ratio (HR) based in outcomes as survival and progressive-free survival, greater than or less than .5 was considered "large" and those greater than .5 were considered "not large". For single-arm studies, which by definition included a lack a control group, we selected a historical control ("best control available") to estimate the magnitude of effect ([Fig 1](#pone.0236345.g001){ref-type="fig"}). If the drug had a biomarker (EGFR, ALK, BRAF or ROS-1) and there was a previous FDA approved drug for the same indication and treatment line, then this drug was selected as the control. However, for drugs without a biomarker or a previous FDA approved comparator we used a historical control from the "Major Milestones against Cancer Timeline for Lung cancer" \[[@pone.0236345.ref015]\], available at the ASCO website. Additionally, when necessary we consulted the NCCN Guidelines for Non-small lung cancer \[[@pone.0236345.ref016]\] and Small Cell lung cancer \[[@pone.0236345.ref017]\].

![Selection of historical controls to estimate effect sizes in single-arms studies.](pone.0236345.g001){#pone.0236345.g001}

Statistical analysis {#sec005}
--------------------

The main variables were grouped into the following binary categories: RCT (blinded and open-label) vs single-arm; surrogate outcomes (OvRR, ORR and PFS) vs overall survival; sample sizes of≥200 vs \<200 (following Ladanie et al., 2019 \[[@pone.0236345.ref018]\] recommendations); and magnitude of effect as large vs not large. Study characteristics were compared between accelerated and regular approvals and this analysis was repeated for BTD for approvals from 2012 onwards, comparing BTD vs non-BTD, the absolute number and percentage was presented. We plotted effect sizes from Accelerated Approval Pathway and BTD according to its effect size measurement; one graph for studies based in hazard ratio (time to event outcome: OS and PFS) and another graph to studies based in RR estimated from single-arms studies using response rate as the primary endpoint.

The study was primarily descriptive, and we included all data available for lung cancer treatment in the period (2006--2018). The absolute difference (AD) and prevalence ratio (PR) with a confidence interval of 95% based on a Normal approximation of the sampling distribution were calculated. A 2-sided *P* values .05 was used to assess statistical significance by the Fisher's exact test. Analyses were performed in R (R Project for Statistical Computing) version 3.5.3.

Results {#sec006}
=======

Regulatory characteristics {#sec007}
--------------------------

From 2006 to 2018, the FDA granted 33 approvals for new drugs and supplemental indications in lung cancer ([Table 1](#pone.0236345.t001){ref-type="table"}). The approvals excluded and justification are available at Supporting Information ([S1 Table](#pone.0236345.s001){ref-type="supplementary-material"}). 33% (11 of 33) of drugs approved via the accelerated pathway and 42% (14 of 33) received BTD. Priority review designation was granted in 42% (14 of 33) of approvals, concomitantly with other designations in some cases. 30% (10 of 33) of approvals were NEMs.

10.1371/journal.pone.0236345.t001

###### Regulatory characteristics of FDA approvals for lung cancer from 2006 to 2018.

![](pone.0236345.t001){#pone.0236345.t001g}

  Drug name (generic)         Brand name              Approval date   NME   Approval pathway   Designation 1          Designation 2
  --------------------------- ----------------------- --------------- ----- ------------------ ---------------------- -----------------
  Bevacizumab                 AVASTIN                 Oct-06          No    Regular            Not mentioned          Not mentioned
  Pemetrexed                  ALIMTA                  Sep-08          No    Accelerated        Not mentioned          Not mentioned
  Erlotinib                   TARCEVA                 Apr-10          No    Regular            Not mentioned          Not mentioned
  Crizotinib                  XALKORI                 Aug-11          Yes   Accelerated        Not mentioned          Not mentioned
  Erlotinib                   TARCEVA                 May-13          No    Regular            Not mentioned          Not mentioned
  Afatinib                    GILOTRIF                Jul-13          Yes   Regular            Not mentioned          Not mentioned
  Ceritinib                   ZYKADIA                 Apr-14          Yes   Accelerated        Breakthrough therapy   Not mentioned
  Ramucirumab                 CYRAMZA                 Dec-14          No    Regular            Not mentioned          Not mentioned
  Nivolumab                   OPDIVO                  Mar-15          No    Regular            Not mentioned          Not mentioned
  Gefitinib                   IRESSA                  Jul-15          No    Regular            Not mentioned          Not mentioned
  Pembrolizumab               KEYTRUDA                Oct-15          No    Accelerated        Breakthrough therapy   Not mentioned
  Nivolumab                   OPDIVO                  Oct-15          No    Regular            Breakthrough therapy   Not mentioned
  Osimertinib                 TAGRISSO                Nov-15          Yes   Accelerated        Breakthrough therapy   Priority review
  Necitumumab                 PORTAZZA                Nov-15          Yes   Regular            Not mentioned          Not mentioned
  Alectinib                   ALECENSA                Dec-15          Yes   Accelerated        Breakthrough therapy   Priority review
  Crizotinib                  XALKORI                 Mar-16          No    Regular            Breakthrough therapy   Priority review
  Afatinib                    GILOTRIF                Apr-16          No    Regular            Not mentioned          Not mentioned
  Atezolizumab                TECENTRIQ               Oct-16          No    Regular            Breakthrough therapy   Not mentioned
  Pembrolizumab               KEYTRUDA                Oct-16          No    Regular            Breakthrough therapy   Priority review
  Brigatinib                  ALUNBRIG                Apr-17          Yes   Accelerated        Breakthrough therapy   Priority review
  Pembrolizumab               KEYTRUDA                May-17          No    Accelerated        Priority review        Not mentioned
  Dabrafenib and trametinib   TAFINLAR and MEKINIST   Jun-17          No    Regular            Breakthrough therapy   Not mentioned
  Afatinib                    GILOTRIF                Jan-18          No    Regular            Priority review        Not mentioned
  Durvalumab                  IMFINZI                 Feb-18          No    Regular            Breakthrough therapy   Priority review
  Osimertinib                 TAGRISSO                Apr-18          No    Regular            Breakthrough therapy   Priority review
  Nivolumab                   OPDIVO                  Aug-18          No    Accelerated        Priority review        Not mentioned
  Dacomitinib                 VIZIMPRO                Sep-18          Yes   Regular            Priority review        Not mentioned
  Pembrolizumab               KEYTRUDA                Oct-18          No    Regular            Priority review        Not mentioned
  Lorlatinib                  LORBRENA                Nov-18          Yes   Accelerated        Breakthrough therapy   Priority review
  Atezolizumab                TECENTRIQ               Dec-18          No    Regular            Not mentioned          Not mentioned

NME: new molecular entity (1st FDA approval).

### Study characteristics {#sec008}

Thirty-seven studies formed the basis of the 33 approvals ([Table 2](#pone.0236345.t002){ref-type="table"}). Single-arms studies and open-label RCTs accounted for 43% (16 of 37), with blinded RCTs for an additional 14% (5 of 37). OS was reported in 46% (17 of 37) of the studies and was specified as the primary endpoint in 30% (11 of 37). PFS, ORR and OvRR were the primary endpoint in 27% (10 of 37), 30% (11 of 37) and 13% (5 of 37) of studies, respectively.

10.1371/journal.pone.0236345.t002

###### Characteristics of studies of lung cancer approvals by the FDA from 2006 to 2018.

![](pone.0236345.t002){#pone.0236345.t002g}

  Drug name (generic)         Approval date   N.st   Study design         Intervention arm                                                                                        Control arm                                            Sample size               OS reported?   Primary endpoint   Effect size calculated (95%CI)   Magnitude of effect
  --------------------------- --------------- ------ -------------------- ------------------------------------------------------------------------------------------------------- ------------------------------------------------------ ------------------------- -------------- ------------------ -------------------------------- --------------------------------------------------
  Bevacizumab                 Oct-06          1      RCT open-label       bevacizumab+ carboplatin and paclitaxel                                                                 carboplatin and paclitaxel                             878                       Yes            OS                 HR: 0.80 (NM)                    Not large
  Pemetrexed                  Sep-08          1      RCT open-label       pemetrexed + cisplatin                                                                                  gemcitabine + cisplatin                                1725                      Yes            OS                 HRa: 0.94 (0.84--1.05)           Not large [^a^](#t002fn002){ref-type="table-fn"}
  Erlotinib                   Apr-10          1      RCT double-blind     erlotinib                                                                                               placebo orally                                         889                       Yes            PFS                HR: 0.71 (0.62--0.82)            Not large
  Crizotinib                  Aug-11          2.1    A\) Single-arm       crizotinib                                                                                              no control                                             136                       NM             ORR                RRc: 2.64 (2.15--3.24)           Large
  Crizotinib                  Aug-11          2.2    B\) Single-arm       crizotinib                                                                                              no control                                             119                       NM             ORR                RRc: 3.22 (2.67--3.88)           Large
  Erlotinib                   May-13          1      RCT open-label       erlotinib                                                                                               platinum-based doublet chemotherapy                    174                       Yes            PFS                HR: 0.34 (0.23--0.49)            Large
  Afatinib                    Jul-13          1      RCT open-label       afatinib                                                                                                pemetrexed/cisplatin                                   345                       NM             PFS                HR: 0.58 (0.43--0.78)            Not large
  Ceritinib                   Apr-14          1      Single-arm           certinib                                                                                                no control                                             163                       NM             ORR                RRc: 0.68 (0.55--0.83)           Not large
  Ramucirumab                 Dec-14          1      RCT double-blind     ramucirumab+docetaxel                                                                                   placebo+docetaxel                                      1253                      Yes            OS                 HR: 0.86 (0.75--0.98)            Not large
  Nivolumab                   Mar-15          2.1    A\) RCT open-label   nivolumab                                                                                               docetaxel                                              272                       Yes            OS                 HR: 0.59 (0.44--0.79)            Not large
  Nivolumab                   Mar-15          2.2    B\) Single-arm       nivolumab                                                                                               NA                                                     117                       NM             ORR                RRc: 1.71 (0.86--3.42)           Not large [^a^](#t002fn002){ref-type="table-fn"}
  Gefitinib                   Jul-15          2.1    A\) Single-arm       gefitinib                                                                                               no control                                             106                       NM             ORR                RRc: 2.64 (2.11--3.30)           Large
  Gefitinib                   Jul-15          2.2    B\) RCT open-label   gefitinib                                                                                               carboplatin/paclitaxel                                 186                       NM             PFS exA            HR: 0.54 (0.38--0.79)            Not large
  Pembrolizumab               Oct-15          1      Single-arm           pembrolizumab                                                                                           no control                                             61                        NM             ORR                RRc: 7.04 (3.06--16.19)          Large
  Nivolumab                   Oct-15          1      RCT open-label       nivolumab                                                                                               docetaxel                                              582                       Yes            OS                 HR: 0.73 (0.60--0.89)            Not large
  Osimertinib                 Nov-15          2.1    A\) Single-arm       osimertinib                                                                                             no control                                             201                       NM             ORR                RRc: 6.47 (4.75--8.82)           Large
  Osimertinib                 Nov-15          2.2    B\) Single-arm       osimertinib                                                                                             no control                                             210                       NM             ORR                RRc: 6.92 (5.10--9.39)           Large
  Necitumumab                 Nov-15          1      RCT open-label       necitumumab+gemcitabine and cisplatin                                                                   gemcitabine and cisplatin (alone)                      1093                      Yes            OS                 HR 0.84 (0.74--0.96)             Not large
  Alectinib                   Dec-15          2.1    A\) Single-arm       alectinib                                                                                               no control                                             87                        NM             ORR                RRc: 0.86 (0.63--1.18)           Not large [^a^](#t002fn002){ref-type="table-fn"}
  Alectinib                   Dec-15          2.2    B\) Single-arm       alectinib                                                                                               no control                                             138                       NM             ORR                RRc: 1.00 (0.77--1.29)           Not large [^a^](#t002fn002){ref-type="table-fn"}
  Crizotinib                  Mar-16          1      Single-arm           crizotinib                                                                                              no control                                             50                        NM             ORR                RRc: 3.48 (2.76--4.39)           Large
  Afatinib                    Apr-16          1      RCT open-label       afatinib                                                                                                Erlotinib                                              795                       Yes            PFS                HR: 0.82 (0.68--0.99)            Not large
  Atezolizumab                Oct-16          2.1    A)RCT open-label     atezolizumab                                                                                            docetaxel                                              1137 (Both studies A+B)   Yes            OS                 HR: 0.74 (0.63--0.87)            Not large
  Atezolizumab                Oct-16          2.2    B\) RCT open-label   atezolizumab                                                                                            docetaxel                                              1137 (Both studies A+B)   Yes            OS                 HR: 0.69 (0.52--0.92)            Not large
  Pembrolizumab               Oct-16          1      RCT open-label       pembrolizumab                                                                                           platinum-based chemotherapy                            305                       Yes            PFS                HR: 0.50 (0.37--0.68)            Large
  Brigatinib                  Apr-17          1      Single-arm           brigatinib                                                                                              no control                                             110                       NM             OvRR               RRc: 1.27 (0.94--1.17)           Not large [^a^](#t002fn002){ref-type="table-fn"}
  Pembrolizumab               May-17          1      RCT open-label       pembrolizumab+pemetrexed and carboplatin                                                                pemetrexed and carboplatin                             123                       NM             PFS                HR: 0.53 (0.31--0.91)            Not large
  Dabrafenib and trametinib   Jun-17          1      Single-arm           dabrafenib and trametinib                                                                               no control                                             36                        NM             OvRR               RRc: 3.22 (2.72--3.81)           Large
  Afatinib                    Jan-18          1      Single-arm           afatinib                                                                                                no control                                             32 (total of 3 studies)   NM             OvRR               RRc: 1.32 (0.97--1.81)           Not large [^a^](#t002fn002){ref-type="table-fn"}
  Durvalumab                  Feb-18          1      RCT double-blind     durvalumab                                                                                              placebo                                                713                       Yes            PFS exA            HR: 0.52 (0.42--0.65)            Not large
  Osimertinib                 Apr-18          1      RCT double-blind     osimertinib                                                                                             gefitinib or erlotinib                                 556                       NM             PFS exA            HR: 0.46 (0.37--0.57)            Large
  Nivolumab                   Aug-18          1      Single-arm           nivolumab                                                                                               no control                                             109                       NM             OvRR               RRc: 1.70 (0.64--4.57)           Not large [^a^](#t002fn002){ref-type="table-fn"}
  Dacomitinib                 Sep-18          1      RCT open-label       dacomitinib                                                                                             gefitinib                                              452                       Yes            PFS                HR: 0.59 (0.47--0.74)            Not large
  Pembrolizumab               Oct-18          1      RCT double-blind     pembrolizumab+ carboplatin and paclitaxel or nab-paclitaxel                                             placebo+carboplatin and paclitaxel or nab-paclitaxel   559                       Yes            OS                 HR 0.64 (0.49--0.85)             Not large
  Lorlatinib                  Nov-18          1      Single-arm           lorlatinib                                                                                              no control                                             215                       NM             OvRR               RRc: 0.90 (0.72--1.14)           Not large [^a^](#t002fn002){ref-type="table-fn"}
  Atezolizumab                Dec-18          1      RCT open-label       atezolizumab + bevacizumab, paclitaxel, and carboplatin OR atezolizumab + paclitaxel, and carboplatin   bevacizumab, paclitaxel, and carboplatin               800                       Yes            OS                 HR: 0.78 (0.64--0.96)            Not large
  Atezolizumab                Dec-18          1      RCT open-label       atezolizumab                                                                                            docetaxel                                              850                       Yes            OS                 HR: 0.74 (0.63--0.87)            Not large

HR: hazard ratio, NM: not mentioned, OS: overall survival, OvRR: overall response rate, ORR: objective response rate, PFS: progressive-free survival, PFS exA: progressive-free survival with explanatory analysis, RCT: randomized controlled trial, RRc: risk ratio calculated.

^a^ Not large and crossed the null effect.

Elements related to the quality of evidence in lung cancer approvals {#sec009}
--------------------------------------------------------------------

### Accelerated vs regular pathway {#sec010}

The single-arm trials and small sample sized were observed 4.06 and 2.37 more times in the Accelerated pathway compared to the Regular pathway, with an absolute difference of 64% and 40%, respectively ([Table 3](#pone.0236345.t003){ref-type="table"}). However, the number of trials with larger effect size was not different among the pathways.

10.1371/journal.pone.0236345.t003

###### Characteristics of studies used to support FDA lung cancer approvals (2006 to 2018) made via the accelerated vs regular pathways and BTD vs non-BTD.

![](pone.0236345.t003){#pone.0236345.t003g}

  Study characteristics   *Accelerated vs regular pathways*   *Breakthrough therapy designation (BTD) vs non-BTD*                                                                          
  ----------------------- ----------------------------------- ----------------------------------------------------- ------------------- --------- --------- --------- -------------------- -------
  **Study design**                                                                                                                                                                         
  Single-arm              11 (85)                             5 (21)                                                4.06 (1.80--9.16)   \< .001   10 (62)   4 (25)    2.50 (0.99--6.33)    0.073
  RCT                     2 (15)                              19 (79)                                               6 (38)              12 (75)                                            
  **Outcome type**                                                                                                                                                                         
  Surrogate endpoint      12 (92)                             14 (58)                                               1.58 (1.09--2.30)   0.057     13 (81)   10 (62)   1.30 (0.83--2.30)    0.43
  Overall survival        1 (8)                               10 (42)                                               3 (19)              6 (38)                                             
  **Sample size**                                                                                                                                                                          
  \<200                   9 (69)                              7 (29)                                                2.37 (1.15--4.88)   0.036     9 (56)    9 (56)    2.37 (0.54--1.84)    1.0
  ≥200                    4 (31)                              17 (71)                                               7 (44)              7 (44)                                             
  **Effect size**                                                                                                                                                                          
  Large                   5 (38)                              6 (25)                                                1.54 (0.58--4.08)   0.27      7 (44)    2 (13)    3.50 (0.85--14.34)   0.11
  Not large               8 (62)                              18 (75)                                               9 (56)              14 (87)                                            

Accelerated pathway are 1.58 (CI95% 1.09--2.30) more likely to have studies with surrogate endpoint and an absolute different between the groups of 37% was observed, however p-value was in the limit of the significance, according to Fisher's exact test, probably due to small sample size.

Graphs 1 and 2 shows that most studies approved using the Accelerated pathway were based in relative risk calculation (from single-arm studies) and only 5 studies showed a large effect size (Graph 2).

![Accelerated approval (red), Scatter plot distribution of each study effect sizes measured with hazard ratio as primary endpoint.\
Studies using Overall Survival were represented with the triangle and Studies using Progressive-Free Survival were represented with the Circle. Color RED referred to accelerated approval pathway and the BLACK referred to regular pathway.](pone.0236345.g002){#pone.0236345.g002}

![Accelerated approval (red), Scatter plot distribution of each study effect sizes measured with risk ratio calculated from studies using response rate as primary endpoint.\
All Studies (circle) were single arms, response rate was the primary endpoint and we calculated the risk ratio estimated by using historical control. Color RED referred to accelerated approval pathway and the BLACK referred to regular pathway.](pone.0236345.g003){#pone.0236345.g003}

### Breakthrough therapy designation {#sec011}

Thirty-two approvals were made between 2012 and 2018, of which 16 were granted BTD ([Table 3](#pone.0236345.t003){ref-type="table"}). Single-arms trials were 2.5 more frequent in the group which received the BTD, with an absolute difference of 37%, however this difference was not significant according to Fisher's exact test.

Large effect sizes, surrogate endpoints and small sample sizes were not more common in BTD, with absolute difference of 31%, 19% and 0%, respectively.

Graph 3 and 4 showed that several studies since 2012 received BTD. The majority of the studies which received this designation were based on relative risk calculation (from single-arm studies) (Graph 4), as expected, larger effect sizes were noted in these studies. Details on the historical controls and RR calculations are presented in the Supporting Information---[S2 Table](#pone.0236345.s002){ref-type="supplementary-material"}.

![Breakthrough therapy designation (blue), Scatter plot distribution of each study effect sizes measured with hazard ratio as primary endpoint.\
Studies using Overall Survival were represented with the Triangle and Studies using Progressive-Free Survival were represented with the Circle. Color BLUE referred to Breakthrough therapy designation and the BLACK referred to Non- Breakthrough therapy designation.](pone.0236345.g004){#pone.0236345.g004}

![Breakthrough therapy designation (blue), Scatter plot distribution of each study effect sizes measured with risk ratio calculated from studies using response rate as primary endpoint.\
All Studies (circle) were single-arms, response rate was the primary endpoint and we calculated the risk ratio estimated by using historical control. Color BLUE referred to Breakthrough therapy designation and the BLACK referred to Non- Breakthrough therapy designation.](pone.0236345.g005){#pone.0236345.g005}

Discussion {#sec012}
==========

We assessed characteristics of the evidence base for FDA lung cancer approvals between 2006 and 2018. Accelerated pathway approvals were 4.06 times more based on single-arm studies, studies with small sample sizes and surrogate primary endpoints. These results are expected given the purpose of accelerated approval is to provide the public more rapid access to new therapies. However, there was no difference in effect sizes between accelerated and regular approvals, likely because regular approvals used surrogate endpoints more often than overall survival. Such a finding is concerning because overall survival is the main patient-centered endpoint. It has previously been shown that surrogate endpoints tend to be associated with larger effect sizes compared to overall survival \[[@pone.0236345.ref019]\]. A recent review addressed the correlation between surrogate endpoints and overall survival with respect to lung cancer, although some studies showed a strong correlation, mostly they were weakly correlated \[[@pone.0236345.ref020]\].

The accelerated pathway was created in 1992 and 25 years later has been described as a "successful program" for oncology drugs with only 5% of drugs withdrawn from market due to failure to demonstrate clinical benefit. The median time for benefit to be verified and conversion from accelerated to regular approval is 3.4 years \[[@pone.0236345.ref021]\]. 85% of the accelerated approvals in the last 25 years were based on response rate outcomes and 72% were based on single-arm studies \[[@pone.0236345.ref021]\]. Considering all FDA approvals between 2005 and 2012, 448 pivotal trials were considered, of which 89.3% were RCTs and 45.3% used surrogate endpoints \[[@pone.0236345.ref012]\]. Similarly, in the present study, 67% of lung cancer approvals were based on surrogate endpoints and only 57% were informed by RCT evidence.

In Evidence-based medicine, core outcome measures are essential for good evidence quality \[[@pone.0236345.ref014]\]. Core outcomes must be patient-centered and clinically relevant. Surrogate endpoints in cancer research have been described as measurable, but not clinically meaningful \[[@pone.0236345.ref022]\]. It is common that a decrease in tumor size or delayed tumor growth is not related to survival gain. While not all surrogate endpoints fail to predict patient-centered outcomes, with a notable example being disease-free survival in colon cancer \[[@pone.0236345.ref023]\], we question the unbridled use of surrogate endpoints to grant market approval. Much has been discussed regarding value-based healthcare and the importance of a patient-centered approach and add their important healthcare results for reimbursement and payment proposals \[[@pone.0236345.ref024]\].

RCTs remain the gold standard for intervention studies and non-controlled studies can only be justified if a dramatic effect is seen \[[@pone.0236345.ref025]\]. Breakthrough approval is intended for drugs that are expected to provide "substantial improvement" in a "clinically significant endpoint over available therapy" \[[@pone.0236345.ref009]\]. Single-arm studies are case series and they carry many uncertainties because the study is not controlled, with uncontrolled patient selection and reporting bias. With no control group, it is difficult to assess effect size properly and impossible to draw causal conclusions \[[@pone.0236345.ref026]\]. The FDA allows phase 1 or phase 2 trials for breakthrough designation. It is encouraging that 37.5% (6 of 16) of BTDs granted for lung cancer were RCTs. Nonetheless, predicting clinical benefit using single-arm trials that measure surrogate endpoints has proven challenging and we recommend revised BTD criteria that align more clearly with BTD's mission.

Patient pressure for new drugs for unmet medical need and market pressure for innovation are used to justify approval of drugs with more uncertainties. However, we found only a small proportion of drugs showing evidence of a large effect size. In general, studies supporting cancer drugs approved by the FDA demonstrate low to modest response rates \[[@pone.0236345.ref027], [@pone.0236345.ref028]\].

A study published in September 2019 assessed the effect size of all drugs and devices that received breakthrough therapy designation since 2012 and were based on nonrandomized clinical trials \[[@pone.0236345.ref029]\]. The authors concluded that 26% of studies in which the FDA did not request further RCTs showed a risk ratio of five or greater. For drugs, it was noted that effect size was larger among studies without RCT requirements. It is notable that the FDA did not properly assess the control group data, which is crucial for effect size estimation in single-arm studies and there is no standardized threshold for effect size \[[@pone.0236345.ref029]\]. Despite this, there is no consensus regarding how large a truly dramatic effect size is. Some authors consider that a risk ratio equal to or larger than 5 to 10 can be safely attributed to the intervention, as it is unlikely to be solely explained by bias or confounding \[[@pone.0236345.ref030]\]. In our study, we took a conservative approach, considering effect sizes of two or greater as large, this was based on the GRADE recommendation. However, despite this more conservative approach, larger effect sizes were not observed in the accelerated pathway.

The argument for expedited approval is that although these studies have significant limitations, they demonstrate large effect sizes. This was not supported in our study. Similarly, elsewhere it has been shown that approvals granted BTD between from 2012 to 2017 were approved 1.9 years earlier than those did not grant this designation. However, there was no difference in the PFS or RRs for solid tumors. In our study, we found that only 44% of the drugs granted BTD had large effect sizes, and the majority demonstrated smaller effects.

Limitations {#sec013}
-----------

Our sample of approvals is small and included only lung cancer treatments. However, lung cancer approvals serve as a suitable case study due to the large quantity of approvals for novel treatments in oncology (targeted drugs and immunotherapies).

We used historical controls in the estimation of effect size in single-arm studies. Although we specified transparently our process of control selection, the choice of historical controls will always be somewhat subjective and could be questioned. Historic controls likely introduce inaccuracies because: (1) the population included in the groups is different, (2) the period when the intervention was tested is different, (3) the available health care technologies and facilities may be different \[[@pone.0236345.ref031]\]. Moreover, we selected the historical control based on the information available to us at the time of writing. However, in reality the FDA may not have had access to this same information because the approvals processes can be concomitant.

We did not assess the bias in the included studies. This can clearly influence the certainty of the evidence. A big challenge is using a tool to assess both RCTs and single-arm studies by the same metrics.

Conclusion {#sec014}
==========

Our results show that effect size was not different between accelerated and regular pathway approvals, despite accelerated approvals being based on more single-arm studies, small sample sizes and surrogate primary endpoints, all of which are related to low evidence quality.

Surrogate endpoints were also more frequent in the accelerated pathway, as expected due to the pathway criteria, however many studies in the regular approval employed surrogate endpoints. Larger effect sizes were more frequent in relative risk estimated from studies based in response rate (single-arms).

More than half the BTD approvals were based on "not large" effect sizes, despite the definition for this designation being demonstration of a dramatic effect size.

Supporting information {#sec015}
======================

###### Details of approvals exclusion and justification.

(DOCX)

###### 

Click here for additional data file.

###### Details of the control selection and risk ratio calculation.

(DOCX)

###### 

Click here for additional data file.

10.1371/journal.pone.0236345.r001
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Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Specifically some methodological issues were raised considering the statistical power of the studies discussed within the paper that should be addressed.

Please submit your revised manuscript within 30 days. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <plosone@plos.org>. When you\'re ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled \'Manuscript\'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

We look forward to receiving your revised manuscript.

Kind regards,

Erika Cecchin

Academic Editor

PLOS ONE

Journal requirements:

When submitting your revision, we need you to address these additional requirements:

1.    Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at <http://www.plosone.org/attachments/PLOSOne_formatting_sample_main_body.pdf> and <http://www.plosone.org/attachments/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2\. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: [http://journals.plos.org/plosone/s/supporting-information](about:blank).

\[Note: HTML markup is below. Please do not edit.\]
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**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Partly

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: I Don\'t Know

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Authors have compared FDA accelerated vs regular pathways approvals and breakthrough therapy designations for lung cancer treatment between 2006 and 2018. The authors concluded that fater approvals are in the majority full of uncertainties which should be viewed with caution and the patient have to be communicated to allow shared decision making.

The manuscript is very well written and informative. It could be accepted for publication.

Reviewer \#2: Ribeiro and co. compared the approved accelerated and approved regular clinical studies. They stated that the "larger effect size" is not different from the accelerated one and the regular approval for FDA lung cancer approvals between 2006 and 2018.

This suggestion is very important, but this statement should be better critically analysed. In particular the final conclusion could be biased, as also suggested by the authors, from the surrogated end points used in regular and accelerated approved studies. The Authors reported the GRADE method, but this method is based on the quality of evidences and substantial end point , i.e. the overall survival. Even if the Authors have evidenced several limitations of the analyses ( surrogate markers, lack of control group,...) they still conclude that there are not differences in the "larger effect size".

Specific comments

• The effect size should be better explained and an explicative table, reporting statistics for all the parameter considered, could be useful

• With regard to the study design, have the statistic power and the sample size been considered?

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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9 Jun 2020

Dear Editor, Dear Reviewers,

Thank for your all useful comments on our manuscript. We have addressed them in the current version and we believe the manuscript has been improved. All changes made to the original version are highlighted in a marked up copy of our manuscript.

Please find our responses below.

Yours sincerely,

Tatiane Ribeiro

Reviewer \#1: Authors have compared FDA accelerated vs regular pathways approvals and breakthrough therapy designations for lung cancer treatment between 2006 and 2018. The authors concluded that fater approvals are in the majority full of uncertainties which should be viewed with caution and the patient have to be communicated to allow shared decision making.

The manuscript is very well written and informative. It could be accepted for publication.

Thanks. Nothing to add.

Reviewer \#2: Ribeiro and co. compared the approved accelerated and approved regular clinical studies. They stated that the "larger effect size" is not different from the accelerated one and the regular approval for FDA lung cancer approvals between 2006 and 2018.

This suggestion is very important, but this statement should be better critically analysed.

In particular the final conclusion could be biased, as also suggested by the authors, from the surrogated end points used in regular and accelerated approved studies. The Authors reported the GRADE method, but this method is based on the quality of evidences and substantial end point , i.e. the overall survival. Even if the Authors have evidenced several limitations of the analyses ( surrogate markers, lack of control group,...) they still conclude that there are not differences in the "larger effect size".

Thanks for the comments, we clarified these aspects in the conclusion.

Specific comments

• The effect size should be better explained and an explicative table, reporting statistics for all the parameter considered, could be useful

We are grateful for the reviewer's comments, we already information regarding table 1, table 2 and supplemental material that explain raw data. In order to add information regarding effect sizes, according to reviewers suggestion we opted to create Graphs (Graph 1-4) to demonstrate effect sizes differences in Accelerated approval pathway and Breakthrough therapy designation.

• With regard to the study design, have the statistic power and the sample size been considered?

We included this information at the Methods session: "The studies were primarily descriptive, and we included all data available for lung cancer treatment in the period (2006-2018)."

Thus, as we included all the information available of studies used to approval for lung cancer treatment, power calculation is not necessary.

###### 
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Click here for additional data file.
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**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed
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2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes
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3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: (No Response)

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: (No Response)

Reviewer \#2: Yes
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6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)
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7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.
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